Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
JAMA Network Open · 2024
DOI: 10.1001/jamanetworkopen.2024.39434 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA Network Open, 2024. Verfasst von Soumyajit Roy und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Thiohydantoins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Preclinical studies suggest that exposure to prostate-directed local therapy (LT) may influence the efficacy of subsequent systemic therapy including androgen receptor pathway inhibitors. However, there is insufficient clinical evidence to support this premise in patients with nonmetastatic castrate-resistant prostate cancer (nmCRPC).
Objective
To determine whether exposure to prior prostate-directed LT (radical prostatectomy [RP], radiation therapy [RT], or both) played any effect-modifying role in the treatment effect of apalutamide on metastasis-free survival (MFS) and overall survival (OS) in patients with nmCRPC. Design, Setting, and Participants This post hoc secondary analysis used individual patient data from SPARTAN (Study of Apalutamide [ARN-509] in Men With Non-Metastatic Castration-Resistant Prostate Cancer), a phase 3, double-blinded, placebo-controlled randomized clinical trial conducted at 332 sites in 26 countries. Between October 14, 2013, and December 15, 2016, patients with nmCRPC and a prostate-specific antigen doubling time of 10 months or less were randomly assigned to apalutamide vs placebo; all patients received androgen deprivation therapy. The final data analysis was performed on December 31, 2023. Exposure Prior prostate-directed LT. Main Outcomes and Measures Separate Cox proportional hazards regression models were constructed for OS and MFS, which included prior LT, treatment group, and an interaction term, in addition to a minimally sufficient set of confounders. Adjusted hazard ratios (HRs) with 95% CIs for MFS and OS were determined for the apalutamide groups with or without prior LT.
Results
Among the 1179 evaluable patients included in this analysis, 795 received prior LT and 384 did not. The median age of patients with and without prior LT was 70 (IQR, 45-90) years and 75 (IQR, 50-95) years, respectively. The median follow-up was 52.0 (IQR, 51.5-52.8) months. A differential treatment effect of apalutamide on MFS was observed between patients with and without prior LT ( P for interaction = .009), with greater benefits for those with prior LT (adjusted HR, 0.22 [95% CI, 0.17-0.27]) compared with those without prior LT (adjusted HR, 0.35 [95% CI, 0.25-0.51]). However, there was insufficient evidence of a differential treatment effect on OS among subgroups stratified by exposure to prior LT ( P for interaction = .23), with improved OS in the subgroup with prior LT (adjusted HR, 0.72 [95% CI, 0.57-0.92]) but no significant difference in OS in the subgroup without prior LT (adjusted HR, 0.92 [95% CI, 0.64-1.31]). Conclusions and Relevance This post hoc analysis of the SPARTAN trial provides evidence of an interaction between prior LT and apalutamide in patients with nmCRPC, with a clinically significant and more favorable treatment effect from apalutamide on MFS among patients with prior LT. Further studies are needed to validate these findings. Trial Registration ClinicalTrials.gov Identifier: NCT01946204
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois.
- Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.
- Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada.
- Public Health, School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.
- Guy's and St Thomas' NHS Foundation Trust and Sarah Cannon Research Institute, London, United Kingdom.
- University of California, Los Angeles.
Zitieren
APA
Roy, S., Malone, S., Wing, K., Chowdhury, S., Kishan, A. U., Sun, Y., Wallis, C. J. D., Mohamad, O., Jia, A. Y., Swami, U., Zaorsky, N. G., Morgan, S. C., Ong, M., Agarwal, N., Spratt, D. E., Small, E. J., & Saad, F. (2024). Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.39434
Vancouver
Roy S, Malone S, Wing K, Chowdhury S, Kishan AU, Sun Y, et al. Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.39434
BibTeX
@article{Roy2024,
author = {Roy, Soumyajit and Malone, Shawn and Wing, Kevin and Chowdhury, Simon and Kishan, Amar U and Sun, Yilun and Wallis, Christopher J D and Mohamad, Osama and Jia, Angela Y and Swami, Umang and Zaorsky, Nicholas G and Morgan, Scott C and Ong, Michael and Agarwal, Neeraj and Spratt, Daniel E and Small, Eric J and Saad, Fred},
title = {Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer},
journal = {JAMA Network Open},
year = {2024},
doi = {10.1001/jamanetworkopen.2024.39434}
}
EUVIMED